Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IO102 · 1 trial · 1 indication
Dose Limiting Toxicity graded per Common Terminology Criteria for Adverse Events (CTCAE) version 4.03
Objective Response Rate (ORR) evaluated by RECIST 1.1 and defined as the rate of complete response (CR) + partial response (PR)
| Arm | Type | Description |
|---|---|---|
| Cohort A1 | EXPERIMENTAL | Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle |
| Cohort A2 | ACTIVE_COMPARATOR | Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle |
| Cohort B1 | EXPERIMENTAL | Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle |
| Cohort B2 | ACTIVE_COMPARATOR | Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle |
| Name | Type | Description |
|---|---|---|
| IO102 | BIOLOGICAL | test immunotherapy |
| pembrolizumab (Keytruda) | BIOLOGICAL | anti-PD-1 immunotherapy |
| Carboplatin (Carboplatin Kabi) | DRUG | chemotherapy |
| Pemetrexed (Pemetrexed Alvogen) | DRUG | chemotherapy |
Inclusion Criteria: * Histologically or cytologically confirmed metastatic NSCLC or non squamous NSCLC * Have biomarker-positive solid tumor * Male participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study medication through 1...
IO102 is an investigational monoclonal antibody being studied for the treatment of non-small cell lung cancer (NSCLC). It is being evaluated as a first-line treatment for metastatic NSCLC in combination with pembrolizumab, with or without chemotherapy. The drug is currently in Phase 1 clinical development.
IO102 is a monoclonal antibody designed to target a specific molecular pathway involved in cancer. As a therapeutic antibody, it is intended to modulate the immune response against tumor cells. The exact molecular target of IO102 has not been disclosed in the available information.
IO102 is being developed by IO Biotech, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol IOBT. IO Biotech is responsible for the clinical development and regulatory strategy for IO102.
IO102 is currently in Phase 1 clinical development. It has completed a Phase 1 trial in patients with metastatic NSCLC. The drug has not yet been approved by regulatory authorities and remains an investigational agent under clinical investigation.
IO102 has been studied in one clinical trial, identified as NCT03562871. This Phase 1 trial evaluated IO102 in combination with pembrolizumab, with or without chemotherapy, as first-line treatment for metastatic NSCLC. The trial enrolled 109 participants and has been completed.
IO102 is not known to have any alternative names. It is a distinct investigational monoclonal antibody developed by IO Biotech. No other names or aliases for IO102 have been reported in the available information.